For Over a Decade, No Systemic Therapy Has Shown Survival Superior to Sorafenib 1,6,7

TECENTRIQ + Avastin, the first and only cancer immunotherapy combination in 1L unresectable or mHCC, redefines treatment expectations with 1,6:

*TECENTRIQ can be administered q4w, q3w, or q2w.
1L=first line; mHCC=metastatic hepatocellular carcinoma; OS=overall survival; q4w=every 4 weeks; q3w=every 3 weeks; q2w=every 2 weeks.

HCC Video Series: discover more about the IMbrave150 trial and clinical experiences